---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-080027"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:24:00.165399+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma appoints Dr. Michael Panzara to board effective March 18, 2022

## Summary
- Dr. Panzara, CMO at Wave Life Sciences, appointed Class I director with term expiring at 2024 annual meeting.
- He brings over 20 years CNS drug development experience, including leadership at Sanofi Genzyme and Biogen.
- Compensation includes initial stock option grant; no transactions with the company or its affiliates.
- Press release notes his role in global regulatory approvals of MS drugs LEMTRADA, AUBAGIO, and TYSABRI.

## SEC filing metadata
- accession: 0001193125-22-080027
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/0001193125-22-080027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/d277480d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-080027
- JSON: https://secwatch.observer/filing/0001193125-22-080027.json
- Plain text: https://secwatch.observer/filing/0001193125-22-080027.txt

## Key facts
- Executive change
  Michael Panzara was appointed as director at LeonaBio, Inc..
  - Action: appointed
  - Role: director
  source text: appointed Dr. Michael Panzara as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/0001193125-22-080027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.